Investigational Laser Focal Therapy (LITT or FLA) for Prostate Cancer
Once the tumor lesion has been detected and diagnosed, the final step in prostate cancer management is the treatment. Focal laser ablation (FLA) is an investigational procedure.
Learn more about focal laser ablation:
Focal laser ablation is a localized procedure available as an investigational therapy (ongoing clinical trial )
Real-time monitoring with MRI can allow targeting the laser probe to specific tumor lesions
Reduced chances of urinary incontinence
Reduced risks of erectile dysfunction
Same-day out-patient procedure
Conscious sedation, no general anesthesia required
Reduced pain and low risks of infection
Repeat procedures can be performed in the future
Prostate Cancer Clinical Trial at DMI:
The first case of focal laser ablation in the world was performed by Dr. John Feller, Dr. McNichols, and Ms. Greenwood on May 2010 as part of a Phase I Clinical Trial.
In 2010 the team of Bernadette Greenwood, BSc, PG Cert., RT(R)(MR) and Roger J. McNichols, PhD developed a unique approach using the Visualase® Thermal Therapy System and the Invivo DynaCAD/DynaTRIM prostate biopsy system to perform Laser Interstitial Thermal Therapy (LITT) or Focal Laser Ablation (FLA) and began conducting an IRB-approved Clinical Trial, NCT 02243033.
Find out if you are eligible for laser focal therapy (LITT or FLA) investigational trial
For “treatment-naive” patients (no prior therapy for prostate cancer)
If you are age 45 or older and have been diagnosed with low/ intermediate-risk prostate cancer confined to the prostate gland
Clinical stage T1c or T2
MR-guided biopsy confirmation of one or more MRI-visible prostate lesion(s) with a Gleason score of 7 (3+4 or 4+3) or less
Tolerance for anesthesia/sedation
Ability to give informed consent
At least 6 weeks since any previous prostate biopsy
Additional criteria can be discussed with our clinicians prior to enrollment
Individuals with recurrent prostate cancer may also consider enrollment under the referral of the treating physician
The current standard of care for aggressive prostate cancer is either the surgical radical removal of the prostate gland and/or whole gland radiation.
Some common side effects with these procedures are:
Urinary incontinence in nearly 50% of men
Erectile dysfunction and impotence
Urinary tract infection
Potential injury to the rectum
Narrowing stricture of the urethra
Collectively these symptoms lead to a diminished quality of life post-surgery.
According to the U.S. Preventive Services Task Force’s statement in May 2018, “more harm than good was being done to men who underwent screening, biopsy and surgical removal of their prostate gland”.
Participating in this study is completely voluntary
IF YOU ARE INTERESTED IN JOINING THIS STUDY, PLEASE CONTACT THE RESEARCH TEAM BELOW
TALK TO A CLINICIAN
IF YOU ARE INTERESTED IN JOINING THIS STUDY, PLEASE CONTACT THE RESEARCH TEAM
John F. Feller, M.D.
Ms. Bernadette M. Greenwood,
BSc, PG Cert., RT (R) MR)
Data Manager/Research Coordinator:
Research Fax - 888-317-9823